[company_age]unknown[/company_age][employees]11-50 employees[/employees][funding]Seed[/funding][description]a:head bio AG is a biotechnology company that is pioneering a new approach to drug discovery for neurological disorders. The company's proprietary technology platform is based on the use of human cerebral organoids, which are 3D tissue cultures that closely resemble the human brain. This technology allows a:head to develop drugs that are more effective and have fewer side effects than traditional drugs. a:head is currently developing drugs for a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The company is headquartered in Vienna, Austria, and has raised over €20 million in funding.[/description][ps]Drug discovery for neurological disorders using human cerebral organoids.[/ps]